NO920493L - Biphasic, transdermal drug delivery device - Google Patents

Biphasic, transdermal drug delivery device

Info

Publication number
NO920493L
NO920493L NO92920493A NO920493A NO920493L NO 920493 L NO920493 L NO 920493L NO 92920493 A NO92920493 A NO 92920493A NO 920493 A NO920493 A NO 920493A NO 920493 L NO920493 L NO 920493L
Authority
NO
Norway
Prior art keywords
drug
drug delivery
biphasic
delivery
delivery device
Prior art date
Application number
NO92920493A
Other languages
Norwegian (no)
Other versions
NO920493D0 (en
Inventor
Jesus Miranda
Gary W Cleary
Original Assignee
Cygnus Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/394,096 external-priority patent/US5091186A/en
Application filed by Cygnus Research Corp filed Critical Cygnus Research Corp
Publication of NO920493D0 publication Critical patent/NO920493D0/en
Publication of NO920493L publication Critical patent/NO920493L/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

Transdermalt medlkament-leveringssystem (10) hvori medlkaraentleverlng er blfaslsk, er tilvelebragt. Medlkamentet blir levert ved en terapeutisk effektiv hastighet l løpet av en begynnende leverlngsfase, vanligvis på omtrent 10 til 14 timer, etterfulgt av en påfølgende sekundær fase, hvor det omtrent Ikke blir levert noe medikament. Vesentlig hele mengden av medikamentet som opprinnelig blir applisert l anord- ningen, blir levert i lepet av den begynnende lever- ingsfasen.Transdermal drug delivery delivery system (10) in which drug delivery is successful is provided. The drug is delivered at a therapeutically effective rate during an initial delivery phase, usually about 10 to 14 hours, followed by a subsequent secondary phase, with virtually no drug being delivered. Substantially the entire amount of the drug initially applied to the device is delivered during the initial delivery phase.

NO92920493A 1989-08-15 1992-02-06 Biphasic, transdermal drug delivery device NO920493L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/394,096 US5091186A (en) 1989-08-15 1989-08-15 Biphasic transdermal drug delivery device
PCT/US1990/004576 WO1991002506A1 (en) 1989-08-15 1990-08-14 Biphasic transdermal drug delivery device

Publications (2)

Publication Number Publication Date
NO920493D0 NO920493D0 (en) 1992-02-06
NO920493L true NO920493L (en) 1992-02-06

Family

ID=26781612

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92920493A NO920493L (en) 1989-08-15 1992-02-06 Biphasic, transdermal drug delivery device

Country Status (1)

Country Link
NO (1) NO920493L (en)

Also Published As

Publication number Publication date
NO920493D0 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
FI920601A0 (en) TVAOFASIG ANORDNING FOER TRANSDERMAL DOSERING AV LAEKEMEDEL.
GEP20063773B (en) Steroid Sulphatase Inhibitors
UA29476C2 (en) Transdermal therapeutic system, containing estradiol
PL324552A1 (en) Plaster for pecutaneous administration of hormones
DK0869808T3 (en) Use of Glu-Trp dipeptides for the preparation of a drug for the treatment of various conditions involving neovascularization
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
TR199801180T2 (en) New compounds with analgesic effect.
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
NO981315L (en) Transdermal matrix system
DK0740650T3 (en) Codrugs as a method of controlled drug transport
ES8802371A1 (en) Process for treating dosage forms
FI953533L (en) Transdermal therapeutic system containing galantamine as active ingredient
IE821214L (en) Medicament
AU2060688A (en) Transdermal therapeutic system
DE68918099D1 (en) PHARMACEUTICAL TREATMENT OF EYE DEVELOPMENT.
WO1996025956A3 (en) Individual medicament dosing conjugate
DK0825865T3 (en) Transdermal therapeutic system for administration of testosterone or testosterone derivative
DE69733268D1 (en) MEDIUM FOR TRANSDERMAL ADMINISTRATION OF MEDICAMENTS
TR199801184T2 (en) New compounds with analgesic action.
BR0011880A (en) Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition
NO985791D0 (en) Device for transdermal administration of trimegestone, method of preparation of the device and its use as a drug
IE46171L (en) N-pyrrolidinylmethylbenzamide derivative.
NO950599L (en) Method of inhibiting HIV replication using IL-4
SE9000207D0 (en) MEDICINAL PRODUCTS AND THE USE OF THE SAME
FR2661180B1 (en) (HYDROXYPROLINE 9) LHRH, ITS PROCESS FOR OBTAINING AND APPLYING AS A MEDICINE.